178 related articles for article (PubMed ID: 24126577)
1. Development of an ex vivo lymph node explant model for identification of novel molecules active against Leishmania major.
Peniche AG; Osorio Y; Renslo AR; Frantz DE; Melby PC; Travi BL
Antimicrob Agents Chemother; 2014; 58(1):78-87. PubMed ID: 24126577
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the in vitro and in vivo antileishmanial activity of a chloroquinolin derivative against Leishmania species capable of causing tegumentary and visceral leishmaniasis.
Soyer TG; Mendonça DVC; Tavares GSV; Lage DP; Dias DS; Ribeiro PAF; Perin L; Ludolf F; Coelho VTS; Ferreira ACG; Neves PHAS; Matos GF; Chávez-Fumagalli MA; Coimbra ES; Pereira GR; Coelho EAF; Antinarelli LMR
Exp Parasitol; 2019 Apr; 199():30-37. PubMed ID: 30817917
[TBL] [Abstract][Full Text] [Related]
3. Ivermectin presents effective and selective antileishmanial activity in vitro and in vivo against Leishmania infantum and is therapeutic against visceral leishmaniasis.
Reis TAR; Oliveira-da-Silva JA; Tavares GSV; Mendonça DVC; Freitas CS; Costa RR; Lage DP; Martins VT; Machado AS; Ramos FF; Silva AM; Ludolf F; Antinarelli LMR; Brito RCF; Chávez-Fumagalli MA; Humbert MV; Roatt BM; Coimbra ES; Coelho EAF
Exp Parasitol; 2021 Feb; 221():108059. PubMed ID: 33338468
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of histamine H1 receptor antagonists azelastine and fexofenadine against cutaneous Leishmania major infection.
Peniche AG; Osorio EY; Melby PC; Travi BL
PLoS Negl Trop Dis; 2020 Aug; 14(8):e0008482. PubMed ID: 32776923
[TBL] [Abstract][Full Text] [Related]
5. Poloxamer 407 (Pluronic(®) F127)-based polymeric micelles for amphotericin B: In vitro biological activity, toxicity and in vivo therapeutic efficacy against murine tegumentary leishmaniasis.
Mendonça DV; Lage LM; Lage DP; Chávez-Fumagalli MA; Ludolf F; Roatt BM; Menezes-Souza D; Faraco AA; Castilho RO; Tavares CA; Barichello JM; Duarte MC; Coelho EA
Exp Parasitol; 2016 Oct; 169():34-42. PubMed ID: 27427166
[TBL] [Abstract][Full Text] [Related]
6. Development of a target-free high-throughput screening platform for the discovery of antileishmanial compounds.
Corman HN; Shoue DA; Norris-Mullins B; Melancon BJ; Morales MA; McDowell MA
Int J Antimicrob Agents; 2019 Oct; 54(4):496-501. PubMed ID: 31323307
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of total phenolic fraction derived from extra virgin olive oil for its antileishmanial activity.
Koutsoni OS; Karampetsou K; Kyriazis ID; Stathopoulos P; Aligiannis N; Halabalaki M; Skaltsounis LA; Dotsika E
Phytomedicine; 2018 Aug; 47():143-150. PubMed ID: 30166099
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of amiodarone in treatment of cutaneous leishmaniasis caused by Leishmania major.
Bemani E; Oryan A; Bahrami S
Exp Parasitol; 2019 Oct; 205():107747. PubMed ID: 31442454
[TBL] [Abstract][Full Text] [Related]
9. In vivo and in vitro antileishmanial activity of Bungarus caeruleus snake venom through alteration of immunomodulatory activity.
Bhattacharya S; Ghosh P; De T; Gomes A; Gomes A; Dungdung SR
Exp Parasitol; 2013 Sep; 135(1):126-33. PubMed ID: 23830987
[TBL] [Abstract][Full Text] [Related]
10. An effective in vitro and in vivo antileishmanial activity and mechanism of action of 8-hydroxyquinoline against Leishmania species causing visceral and tegumentary leishmaniasis.
Costa Duarte M; dos Reis Lage LM; Lage DP; Mesquita JT; Salles BC; Lavorato SN; Menezes-Souza D; Roatt BM; Alves RJ; Tavares CA; Tempone AG; Coelho EA
Vet Parasitol; 2016 Feb; 217():81-8. PubMed ID: 26827866
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo efficacy of ether lipid edelfosine against Leishmania spp. and SbV-resistant parasites.
Varela-M RE; Villa-Pulgarin JA; Yepes E; Müller I; Modolell M; Muñoz DL; Robledo SM; Muskus CE; López-Abán J; Muro A; Vélez ID; Mollinedo F
PLoS Negl Trop Dis; 2012; 6(4):e1612. PubMed ID: 22506086
[TBL] [Abstract][Full Text] [Related]
12. Anti-leishmanial effects of trinitroglycerin in BALB/C mice infected with Leishmania major via nitric oxide pathway.
Nahrevanian H; Najafzadeh M; Hajihosseini R; Nazem H; Farahmand M; Zamani Z
Korean J Parasitol; 2009 Jun; 47(2):109-15. PubMed ID: 19488416
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo antileishmanial activity of a fluoroquinoline derivate against Leishmania infantum and Leishmania amazonensis species.
Tavares GSV; Mendonça DVC; Lage DP; Antinarelli LMR; Soyer TG; Senna AJS; Matos GF; Dias DS; Ribeiro PAF; Batista JPT; Poletto JM; Brandão GC; Chávez-Fumagalli MA; Pereira GR; Coimbra ES; Coelho EAF
Acta Trop; 2019 Mar; 191():29-37. PubMed ID: 30586571
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo antileishmanial activity of 2-amino-4,6-dimethylpyridine derivatives against Leishmania mexicana.
Abdala H; Alvarez N; Delmas F; Di Giorgio C; Robert JM; Le Baut G; Le Pape P
Parasite; 2002 Dec; 9(4):367-70. PubMed ID: 12514953
[TBL] [Abstract][Full Text] [Related]
15. Antileishmanial Activity of Disulfiram and Thiuram Disulfide Analogs in an Ex Vivo Model System Is Selectively Enhanced by the Addition of Divalent Metal Ions.
Peniche AG; Renslo AR; Melby PC; Travi BL
Antimicrob Agents Chemother; 2015 Oct; 59(10):6463-70. PubMed ID: 26239994
[TBL] [Abstract][Full Text] [Related]
16. A chloroquinoline derivate presents effective in vitro and in vivo antileishmanial activity against Leishmania species that cause tegumentary and visceral leishmaniasis.
Sousa JKT; Antinarelli LMR; Mendonça DVC; Lage DP; Tavares GSV; Dias DS; Ribeiro PAF; Ludolf F; Coelho VTS; Oliveira-da-Silva JA; Perin L; Oliveira BA; Alvarenga DF; Chávez-Fumagalli MA; Brandão GC; Nobre V; Pereira GR; Coimbra ES; Coelho EAF
Parasitol Int; 2019 Dec; 73():101966. PubMed ID: 31362122
[TBL] [Abstract][Full Text] [Related]
17. Auranofin is an apoptosis-simulating agent with in vitro and in vivo anti-leishmanial activity.
Sharlow ER; Leimgruber S; Murray S; Lira A; Sciotti RJ; Hickman M; Hudson T; Leed S; Caridha D; Barrios AM; Close D; Grögl M; Lazo JS
ACS Chem Biol; 2014 Mar; 9(3):663-72. PubMed ID: 24328400
[TBL] [Abstract][Full Text] [Related]
18. Leishmania pifanoi pathogenesis: selective lack of a local cutaneous response in the absence of circulating antibody.
Colmenares M; Constant SL; Kima PE; McMahon-Pratt D
Infect Immun; 2002 Dec; 70(12):6597-605. PubMed ID: 12438331
[TBL] [Abstract][Full Text] [Related]
19. A novel Leishmania major amastigote assay in 96-well format for rapid drug screening and its use for discovery and evaluation of a new class of leishmanicidal quinolinium salts.
Bringmann G; Thomale K; Bischof S; Schneider C; Schultheis M; Schwarz T; Moll H; Schurigt U
Antimicrob Agents Chemother; 2013 Jul; 57(7):3003-11. PubMed ID: 23587955
[TBL] [Abstract][Full Text] [Related]
20. Intradermal inoculations of low doses of Leishmania major and Leishmania amazonensis metacyclic promastigotes induce different immunoparasitic processes and status of protection in BALB/c mice.
Courret N; Lang T; Milon G; Antoine JC
Int J Parasitol; 2003 Oct; 33(12):1373-83. PubMed ID: 14527520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
